MedTrace Logo

Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis

NCT05260073 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2024-09-20

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to evaluate patient reported outcomes (PROs) in terms of health-related quality of life (HRQoL) among subjects with actinic keratosis (AK).

Conditions

  • Keratosis, Actinic

Interventions

DRUG

Tirbanibulin

Participants will be treated with tirbanibulin ointment 1% (2.5 mg tirbanibulin in 250 mg) as 1 single-dose packet per application, for 5 consecutive days.

Sponsors & Collaborators

  • Almirall, S.A.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-09
Primary Completion
2022-10-31
Completion
2023-03-07

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05260073 on ClinicalTrials.gov